Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 2Phase 3 1

Status

Recruiting 3Completed 2Terminated 1

Sponsor Class

INDUSTRY 6

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Carcinoma, Non-Small-Cell Lung 87Breast Neoplasms 48Prostatic Neoplasms 43Squamous Cell Carcinoma of Head and Neck 34Lung Neoplasms 24Stomach Neoplasms 19Neoplasms 19Neoplasm Metastasis 16Head and Neck Neoplasms 16Parkinson Disease 4, Autosomal Dominant Lewy Body 14Urinary Bladder Neoplasms 13Carcinoma, Transitional Cell 11Triple Negative Breast Neoplasms 10Ovarian Neoplasms 8Endometrial Neoplasms 8Carcinoma, Squamous Cell 8Adenocarcinoma 8Non-Muscle Invasive Bladder Neoplasms 7HER2-positive Breast Cancer 7Prostatic Neoplasms, Castration-Resistant 6Melanoma 6Carcinoma 6Small Cell Lung Carcinoma 5Nasopharyngeal Carcinoma 5Esophageal Neoplasms 5Advanced Solid Tumors 5Uterine Cervical Neoplasms 4Sarcoma 4Oropharyngeal Neoplasms 4Fallopian Tube Neoplasms 4

Interventions

enzalutamide 10Prednisone 6Docetaxel 6Abiraterone Acetate 4darolutamide 3olaparib 2niraparib 2abiraterone 2Pluvicto 2Nivolumab 2zimberelimab 1xentuzumab 1sacituzumab govitecan 1radium Ra 223 dichloride 1quemliclustat 1ibrutinib 1gedatolisib 1gallium 68 PSMA-11 1fludrocortisone acetate 1cabazitaxel 1TVB-2640 1Rosuvastatin Calcium 1Pioglitazone 1Omeprazole 1JNJ-64619178 1JNJ-64264681 1Ipilimumab 1Gonadotropin-Releasing Hormone 1Dexamethasone 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Prostatic Neoplasms, Castration-Resistant × Docetaxel × 1 year × Clear all
NCT06353386 2026-05-26

MK-5684-01A

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
220 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05848011 2026-05-22

A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

MacroGenics

Phase 2 Completed
154 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT06863272 2026-05-15

IDeate-Prostate02

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting
360 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

NCT07225946 2026-05-11

KLK2-PASenger

Janssen Research & Development, LLC

Phase 3 Recruiting
800 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT04381832 2025-07-22

Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

Arcus Biosciences, Inc.

Phase 1/2 Completed
173 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT05169684 2025-06-10

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Bristol-Myers Squibb

Phase 2 Terminated
10 enrolled 15 charts
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡